Trillium Therapeutics Inc. (NASDAQ:TRIL) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $30.50 for the company and are forecasting that the company will post ($0.82) EPS for the current quarter, according to Zacks. Zacks has also given Trillium Therapeutics an industry rank of 61 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research downgraded shares of Trillium Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 2nd.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 12.61 on Monday. The company’s market cap is $92.65 million. Trillium Therapeutics has a 12 month low of $9.00 and a 12 month high of $29.92. The firm has a 50-day moving average of $13.47 and a 200 day moving average of $16.66.
For more information about research offerings from Zacks Investment Research, visit Zacks.com